Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlight
The FDA declined to approve Summit Therapeutics’ Akeso-partnered ivonescimab, putting other PD-1/VEGF drug developers on notice; Isomorphic bagged a $5 billion series C, the largest in biotech history; ObesityWeek and Clinical Trials on Alzheimer’s Disease conferences in full swing.
comments(0)
5-min edit window · permanent after that